Health
EU Unveils Critical Medicines Act to Secure Drug Supply, But Key Questions Remain
The European Commission has introduced the Critical Medicines Act, a major initiative aimed at strengthening the EU’s access to essential medicines. The proposal, unveiled this week, seeks to reduce dependency on non-EU suppliers, enhance joint procurement, and encourage European production. However, questions remain over its funding, stockpiling strategy, and potential trade risks.
‘Buy European’ Proposal Raises Trade Concerns
One of the Act’s most debated measures is the ‘Buy European’ rule, which would prioritize suppliers manufacturing a significant portion of critical medicines within the EU. The goal is to ensure a more reliable drug supply, but critics warn that this protectionist approach could trigger retaliation from global trade partners.
EU Health Commissioner Olivér Várhelyi defended the policy, calling it “a necessary step for public health security.” However, comparisons have been drawn to China’s ‘Buy China’ policy, which the EU itself has criticized for restricting foreign suppliers. If the EU moves forward with this approach, it could face trade tensions and reduced market access abroad.
Boosting European Production Without Full Relocation
The proposal also aims to reduce reliance on non-EU pharmaceutical production by promoting increased manufacturing within Europe. However, rather than requiring production to be strictly within EU borders, the plan emphasizes bilateral partnerships with neighboring countries such as the UK, Switzerland, and EU candidate nations.
“I rely on our closest neighbors to help bring production closer to the EU,” said Várhelyi, suggesting that strategic supply chain diversification is the Commission’s preferred approach over full relocation.
Funding Challenges Could Limit Impact
A key concern surrounding the Act is funding constraints. The Commission has allocated €83 million for 2026-2027, primarily from the EU4Health program. However, this budget is too small to support large-scale manufacturing shifts, raising doubts about the proposal’s effectiveness.
While additional funding could come from Horizon Europe and the Digital Europe Programme, 11 EU health ministers have called for defense funding to include medicine production, an idea that Várhelyi rejected. Instead, the Commission is loosening state aid restrictions, encouraging member states to fund production efforts themselves.
Strengthening Joint Drug Procurement
To improve purchasing efficiency, the Act enhances the EU’s joint procurement mechanism. Traditionally, the Commission and at least nine member states negotiate as a single bloc to secure better pricing and supply terms. The new proposal expands this approach, allowing the Commission to act as a central buyer upon request.
Additionally, a cross-border procurement model will be introduced, where the Commission provides logistical and administrative support to individual member states handling their own drug purchases.
Stockpiling Strategy Left Out
One of the biggest gaps in the proposal is the lack of a coordinated stockpiling framework. The Critical Medicine Alliance had recommended a harmonized EU-wide contingency stock, ensuring member states share supplies during shortages.
However, this was omitted from the final proposal, sparking concerns of fragmented and inequitable stockpiling across the bloc. Croatian MEP Tomislav Sokol warned that larger countries hoarding supplies at the expense of smaller nations must not happen again.
What’s Next?
As the Critical Medicines Act moves into the legislative process, MEPs are expected to push for amendments, particularly to address stockpiling coordination and funding gaps. While the proposal marks a major step toward securing Europe’s medicine supply, unresolved questions could shape its final impact in the coming months.
Health
Early-Onset Cancer Rates Rising in U.S., But Deaths Mostly Stable, Study Finds

A new U.S. government study has revealed that while cancer diagnoses among people under 50 are on the rise, the overall death rates for most types of cancer in this age group remain stable.
Published Thursday in the journal Cancer Discovery, the study is one of the most comprehensive assessments to date of early-onset cancers, analyzing data from more than two million cases diagnosed in Americans aged 15 to 49 between 2010 and 2019.
The findings show that 14 out of 33 cancer types had increasing incidence rates in at least one younger age group. The most significant increases were seen in breast, colorectal, kidney, and uterine cancers. Women accounted for about 63 percent of the early-onset cases.
“This pattern generally reflects something profound going on,” said Tim Rebbeck of the Dana-Farber Cancer Institute, who was not involved in the study. “We need to fund research that will help us understand why this is happening.”
The study found that, compared to 2010 data, there were 4,800 more breast cancer cases, 2,000 additional colorectal cancers, 1,800 more kidney cancers, and 1,200 extra uterine cancers by 2019.
Despite the rising numbers, researchers emphasized a key reassurance: death rates for most of these cancers are not increasing. However, exceptions were noted—colorectal, uterine, and testicular cancers saw slight rises in mortality among younger adults.
The causes behind the rise in early-onset cancers are not fully understood. The study’s datasets do not include information on potential risk factors such as obesity, lifestyle, or access to healthcare. However, researchers, including lead author Dr. Meredith Shiels of the National Cancer Institute, highlighted obesity as a possible driver.
“Several of these cancer types are known to be associated with excess body weight,” said Dr. Shiels. She also pointed to advances in detection and changing screening practices as possible contributors to earlier diagnoses.
Breast cancer trends may also be influenced by shifting reproductive patterns, such as women having children later in life, which has been associated with increased cancer risk due to fewer years of pregnancy and breastfeeding—factors known to lower risk.
Not all cancer types followed the upward trend. Rates of more than a dozen cancers, including lung and prostate cancer, are decreasing among younger people. Researchers attribute the lung cancer decline to reduced smoking rates, while updated PSA screening guidelines are likely behind the drop in prostate cancer diagnoses.
Experts plan to convene later this year to further investigate the growing early-onset cancer burden and explore targeted prevention strategies.
Health
UK Scientists Develop Tool to Measure ‘Heart Age,’ Offering New Insights for Cardiovascular Health

Researchers in the United Kingdom have developed a new tool that can determine how old a person’s heart is in comparison to their actual age, offering a potential breakthrough in the early detection and prevention of cardiovascular disease.
The study, led by scientists at the University of East Anglia (UEA), examined magnetic resonance imaging (MRI) scans from 557 individuals across the UK, Spain, and Singapore. Of those, 336 participants had known health risk factors such as obesity, high blood pressure, or diabetes.
Using these scans, the researchers measured structural and functional markers of cardiac health — including the size of the heart’s chambers and how effectively it pumps blood. These indicators were then used to create an algorithm that calculates the heart’s “functional age.”
The findings, published in the European Heart Journal, revealed that individuals with cardiovascular risk factors had hearts that were, on average, 4.6 years older than their chronological age. In people with obesity, the gap was even wider, indicating faster cardiac ageing.
“People with health issues like diabetes or obesity often have hearts that are ageing faster than they should – sometimes by decades,” said Dr. Pankaj Garg, a cardiologist and lead author of the study. “This tool gives us a way to visualize and quantify that risk.”
While the tool shows promise, researchers noted some limitations. The model does not account for how long patients had lived with their conditions, and the study group primarily included older individuals who had survived with these health issues — raising concerns about survivor bias. The relatively small sample size also means the tool needs broader validation before it can be widely adopted.
Despite these limitations, the research team believes the tool could have valuable clinical applications in the future. Dr. Garg said it may help doctors counsel patients more effectively about their cardiovascular health and recommend lifestyle changes or treatments to slow heart ageing.
“By knowing your heart’s true age, patients could get advice or treatments to slow down the ageing process, potentially preventing heart attacks or strokes,” he said. “It’s about giving people a fighting chance against heart disease.”
The team hopes the tool could eventually be integrated into routine care, empowering patients to take early steps toward improving their heart health through diet, exercise, and medical intervention.
Health
Global Health Inequities Persist as Progress on Life Expectancy and Mortality Slows, Says WHO
-
Business12 months ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business12 months ago
Recent Developments in Small Business Taxes
-
Politics12 months ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business10 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business10 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology12 months ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics12 months ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Technology12 months ago
Recent Developments in AI Ethics in America